MOUNIA CHAMI PhD-HDR

Course and current status

Education

2001:   PhD in molecular and cellular biology. Paris XI University, France. Host laboratory: INSERM U370, Faculty of Medicine Necker-Enfants malades. Paris V University, France.

2006: Diploma for research direction (HDR). Paris V University, France.

2007: Diploma for animal experimentation, level 1. Veterinary school, Lyon, France.

Work Experience

Since 2011: Senior Research Associate (permanent position, INSERM).  Institute of Molecular and Cellular Pharmacology (IPMC), CNRS UMR-7275, Valbonne, Sophia-Antipolis, France.

2009-2010: Team leader. The Italian Institute of technology, neuroscience and brain technologies department, Genoa, Italy.

2005-2008: INSERM young investigator contract. INSERM U807, Paris V University, Paris, France.

Research direction

Since 2011: CNRS UMR-7275_Principal investigator_ Research project: Endoplasmic reticulum signaling and of mitochondrial structure and function alterations in Alzheimer's disease.

2009-2010: The Italian Institute of technology_Principal investigator_ Research project: Role of calcium signaling in Alzheimer's Disease.

2005-2008: INSERM U807, Paris V University_Principal investigator_Research project: Physiopathology of Endoplasmic Reticulum stress and mitochondrial dysfunction.

Since 2008: Supervision of 6 PhD students (2 ongoing), 8 M.Sc. students, 4 research technicians, and 3 post-doctoral fellows (2 ongoing).

Teaching and mentoring experience

2006-2008: Teaching of molecular biology and biochemistry, and of cellular biology, Paris V University, France.

2006-2010: Teaching of Master 1 and Master 2 degrees, Paris XI University, France, and the Italian Institute of Technology, Genoa, Italy.

2019: Member of the PhD Ministry fellowship reviewing committee (ED85)

2018: Membr of the PhD reviewing committee (principal reviewer) Ceaen Normandie University. France.

2015: Nominated Mentor at INSERM.

2015: Member of the PhD reviewing committee, Sidi Mohammed Ben Abdellah University, Fez, Morocco.

2015: Member of the reviewing committee Polytechnic school, option “genie biology” (GB2), Sophia Antipolis.

Since 2011: Member of the reviewing committee of Master 1 et 2, University Côte d’Azur.

2014: Member of the reviewing committee for Research associate n°66 MCF-1704, Lille University.

2014: Member of the reviewing committee for the diploma of habilitation for research, Sorbonne Université.

Since 2012: Member of « Society of Neuroscience ».

Honors

2020: Scientific excellence price (PEDR) from INSERM

Since 2020: Member of the French scientific advisory board of “Fondation Vaincre Alzheimer”

Since 2019: Member of the reviewing committee of CIEPAL-AZUR "Comité Institutionnel d'Éthique Pour l'Animal de Laboratoire".

2017: Associate Editor of Journal of Alzheimer Disease.

2006: Poster Award of the European Calcium Society (ECS).

2004: Post-doctoral fellowship Roux, Pasteur institute.

2002: Long term post-doctoral fellowship from the European Molecular Biology Organization (EMBO).

2001: National Ph.D. Award of the « Association Nationale des Enseignants de Biologie Cellulaire ».

2001: Post-doctoral fellowship Award from the «Association pour la Recherche sur le Cancer».

2000 : Fellowship from «Fondation pour la Recherche Médicale».

1998: National Ph.D. Fellowship Awards from «la Ligue Nationale Contre le Cancer».

Research Support

2019: Grant from Fondation Vaincre la Maladie d’Alzheimer. PI. (100000 euros)

2019: Grant from IDEX-UCA-JEDI “Living systems Complexity and diversity”, seminar organization. Co-PI. (1500 euros)

2017-2018: Trans-disciplinary master project, IDEX-UCA-JEDI “Living systems Complexity and diversity”. Co-PI. (24000 euros)

2013-2016: Grant from LECMA (Ligue européenne contre la maladie d’Alzheimer/Fondation Vaincre la Maladie d’Alzheimer. PI. (80000 euros)

2008-2011: Grant from Fondation pour la Recherche Médicale. Co-PI with Prof. Paterlini-Bréchot. (240000 euros)

2005-2008: Grant from Association Française contre les myopathies. Co- PI. (80000 euros)

2006: Clinic institute of the mouse. “Generation of S1T transgenic mouse”. PI.

Selected/invited oral communications

2019: Seminar (invited). 6th “Joint Neurobiology IPMC - iBV meeting“, Université Côte d’Azur, Nice, 4th December.

2019: Seminar (invited). Club Alzheimer Montpellier, Genopolys, Montpellier, 26th,-27th November.

2019: Seminar (invited). IPMC, 30 years of biology on the Riviera. Nice, 4th November.

2019: 14th International Conference on Alzheimer's & Parkinson's Diseases. Lisbon, Portugal, 26th-31st Marsh.

2018: Seminar (invited). Institute of Molecular Biosciences, Mahidol University, Bangkok, Thailande, 30th October.

2018: Seminar (invited). Université de Montpellier, INSERM U1198. France, 13th November.

2018: 9th World Congress on Targeting Mitochondria, Berlin, Germany, 24th- 25th October.

2018: “Journées Francophones de la maladie d′Alzheimer et des syndrômes apparentés”, Lille, 11th-14th June.  

2018: Laureates ceremony of “ Fondation Vaincre Alzheimer 2018”, Medicine Academy, Paris, 10th January.

2017: Seminar (invited). Mini Workshop-Neurodegenerative and neuromuscular disorder, Hôpital Cimiez, Nice, 9th November.

2010:  NeuroIITscience Workshop at the IIT Central Research Lab, Genova, 14th‐15th July.

2009: Seminar (invited). The European Brain Research Institute (EBRI), Roma, Italy.

2008: Seminar (invited). Institut de Pharmacologie Moléculaire et Cellulaire, Sophia Antipolis, Valbonne, France.

2007: 14th Congress of Calcium Binding Proteins and Calcium Function in Health and Disease, La Palma, Spain, selection for two oral communications. 16th-21st October.

2006: Annual colloquia of the IRNEM (Necker‐Enfants malades), Dourdan, France.

2004: Annual colloquia of the IRNEM (Necker‐Enfants malades), Dourdan, France.

2002: 10th Euroconference on apoptosis, Pasteur Institute, Paris, France.

Scientific summary

My work has shown the role of calcium signalling deregulation in apoptotic cell death. I have highlighted the role of the contact sites between the endoplasmic reticulum (ER) and the mitochondria known also as MAMs (mitochondria-associated membranes) in the control of apoptosis, mitochondrial respiratory chain deficiency and of ER stress response.  This knowledge prompted me to study the role of calcium signaling deregulation and ER-mitochondria communication in the pathogenesis of Alzheimer's disease (AD). The recently obtained results demonstrate the role of the ryanodine receptor (RyR2) in amyloid precursor protein (APP) metabolism and the production of amyloid beta peptides, and in the development of cognitive deficits and synaptic plasticity dysfunction related to AD. These studies reveal RyR2 as a major molecular determinant in the development and/or progression of AD. Pharmacologic stabilization of RyR2 could be considered as a new therapeutic strategy for AD. My working hypothesis also postulate that the ER-mitochondria contact sites are deregulated in AD, favoring mitochondrial pathology associated with the disease development. Indeed, we have demonstrated the localization and metabolism of APP in MAMs and described the protein interaction of APP and its metabolites in this cellular microdomain. These results also reveal the potential involvement of impaired MAMs function in the deregulation of lipid metabolism related to AD. These results may open the possibility of identifying new molecular targets for the treatment of AD.

Image d’exemple